A Phase 1 interventional study of SYH9017 and Placebo in Overweight or Obesity, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 601 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.
Among the 601 studies in Obesity with a site in China, this one is the 344th largest by planned enrollment of the 503 interventional ones that give a count, is one of 114 that started in 2025, is one of 93 in phase 1, reaches primary completion later than 77 of the 280 other live ones, and was the 327th registered.
11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →221 of the 601 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
601 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 114 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is close to the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 120 across the 503 interventional studies, 310 across the 98 observational. Of the 242 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 601 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is the lead sponsor of 26 studies on the registry; 4 are open to participants now.
CSPC Pharmaceutical Group Limited has 9 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
104 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 104 to your calendar (.ics) → With an account.
Among the 601 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
11,560 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's planned enrollment of 66 is close to the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is the lead sponsor of 26 studies on the registry; 4 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any one of the following criteria is met:
i. Participants with one or more abnormal vital signs: body temperature \<35.5°C or >37.2°C, pulse rate \<50 beats per minute or >100 beats per minute, systolic blood pressure ≥160 mmHg or \<90 mmHg, diastolic blood pressure ≥100 mmHg or \<60 mmHg. A single retest is allowed, and participants with abnormalities in both tests will be excluded; ii. Any of the following laboratory abnormalities: a) Fasting plasma glucose ≥7.0 mmol/L or fasting plasma glucose \<3.9 mmol/L or level >6.5%; b) or ALT >2 times the (ULN), total >1.5 times ULN, deemed by the investigator; c) Estimated (eGFR) \<90 mL/min/1.73m²; d) Serum amylase or lipase >3 times ULN; e) Blood low-density lipoprotein cholesterol (LDL-C) ≥4.40 mmol/L; f) Triglycerides (TG) ≥5.65 mmol/L.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH9017 on Day 1
Drug: SYH9017
Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1
Drug: Placebo
Subjects in MAD experimental groups will receive subcutaneous injection of SYH9017 every 4weeks
Drug: SYH9017
Subjects in MAD placebo groups will receive subcutaneous injection of placebo every 4weeks
Drug: Placebo
Subjects in MAD active comparator groups will receive subcutaneous injection of placebo every weeks
Drug: Wegovy ®
subcutaneous injection once time in SAD and four times in MAD
subcutaneous injection once time in SAD and four times in MAD
subcutaneous injection once a week
Incidence of AEs following single-dose administration of SYH9017 Description:
Time frame: up to 49 days after the dosing
Incidence of AEs following multiple doses administration of SYH9017AEs of SYH 9017 following multiple doses
Time frame: up to 140 days after the last dosing
The Cmax of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The AUC of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The Tmax of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The t1/2 of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The CL/F of SYH9017 following single-dose
Time frame: *Time Frame:up to 49 days after the dosing
The Vz/F of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The proportion of patients (%) who developed binding antibodies and neutralizing antibodies following single-dose administration of SYH9017
Time frame: up to 49 days after the dosing
The percentage change in body weight from baseline of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The percentage change in waist circumference from baseline of SYH9017 following single-dose
Time frame: up to 49 days after the dosing
The Cmax of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The AUC of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The Tmax of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The t1/2 of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The CL/F of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The Vz/F of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The Cmin of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The RAUC of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The RCmax of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The proportion of patients (%) who developed binding antibodies and neutralizing antibodies following multiple doses administration of SYH9017
Time frame: up to 140 days after the last dosing
The percentage change in body weight from baseline of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The percentage change in waist circumference from baseline of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The proportion of participants with ≥5% weight loss during the trial period of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The proportion of participants with ≥10% weight loss during the trial period of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
The changes in body composition (including visceral, peripheral fat, and skeletal muscle) as measured by body fat analyzer after 16 weeks of treatment, compared to baseline of SYH9017 following multiple doses
Time frame: up to 140 days after the last dosing
Started Feb 2025 (actual). Primary completion is estimated for Aug 2026, 17 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 17 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. →